Desmopressin dose requirements in patients with permanent arginine vasopressin deficiency: a tertiary center experience.

Emanuele VaraldoMichela SibillaNunzia PrencipeAlessandro Maria BertonDaniela CuboniLuigi Simone AversaFrancesca MocelliniFabio BiolettoEzio GhigoValentina GascoSilvia Grottoli

Published in: Pituitary (2024)

Our data suggest that patient age appears to be the primary factor associated with the daily sublingual desmopressin dose required to achieve adequate clinical and biochemical control in patients with permanent AVP deficiency.

Keyphrases

nitric oxide
replacement therapy
case report
physical activity
electronic health record
machine learning
artificial intelligence